Andrew Biggin
Overview
Explore the profile of Andrew Biggin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
570
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandy J, Biggin A, Siafarikas A, Simm P, Rodda C, Munns C
J Paediatr Child Health
. 2025 Feb;
PMID: 40012305
X linked hypophosphataemia (XLH) is a systemic, chronic condition that significantly impairs quality of life. In XLH, a phosphate regulating endopeptidase homologue X-linked (PHEX) gene mutation leads to excess fibroblast...
2.
Ward L, Hogler W, Glorieux F, Portale A, Whyte M, Munns C, et al.
JBMR Plus
. 2024 May;
8(1):ziad001.
PMID: 38690124
In a randomized, open-label phase 3 study of 61 children aged 1-12 years old with X-linked hypophosphatemia (XLH) previously treated with conventional therapy, changing to burosumab every 2 weeks (Q2W)...
3.
Sandy J, Nunez C, Wheeler B, Jefferies C, Morris A, Siafarikas A, et al.
Bone
. 2023 Jun;
173:116791.
PMID: 37263386
Background: X-linked hypophosphataemia (XLH) is the most common heritable form of rickets. Prevalence data varies across the literature between 1 in 20,000 and 1 in 200,000 per population. Methods: Australian...
4.
Munns C, Maguire E, Williams A, Wood S, Biggin A
JBMR Plus
. 2023 May;
7(5):e10728.
PMID: 37197318
Craniosynostosis is a rare condition of skull development, manifesting during fetal and early infant development, and is usually congenital. Craniosynostosis secondary to metabolic disorders, such as X-linked hypophosphatemia (XLH), is...
5.
Imel E, Glorieux F, Whyte M, Portale A, Munns C, Nilsson O, et al.
J Clin Endocrinol Metab
. 2023 Apr;
108(11):2990-2998.
PMID: 37084401
Context: In an open-label, randomized, controlled, phase 3 trial in 61 children aged 1 to 12 years with X-linked hypophosphatemia (XLH), burosumab improved rickets vs continuing conventional therapy with active...
6.
Vanderniet J, Tsinas D, Wall C, Girgis C, London K, Keane C, et al.
Calcif Tissue Int
. 2023 Feb;
112(5):592-602.
PMID: 36810677
Aneurysmal bone cysts (ABC) are rare osteolytic, benign but often locally aggressive tumours of the long bones or vertebrae. For spinal ABC, surgical management, embolisation or sclerotherapy alone often carry...
7.
Sandy J, Simm P, Biggin A, Rodda C, Wall C, Siafarikas A, et al.
J Paediatr Child Health
. 2022 Apr;
58(5):762-768.
PMID: 35426466
X-linked hypophosphataemia (XLH), the most common inherited form of rickets, is caused by a PHEX gene mutation that leads to excessive serum levels of fibroblast growth factor 23 (FGF23). This...
8.
Vanderniet J, Wall C, Mullins A, London K, Lim L, Hibbert S, et al.
Bone
. 2022 Mar;
159:116395.
PMID: 35331976
Background: Central giant cell granulomas (CGCG) are rare osteolytic, benign but often locally aggressive tumours of bone. Surgical curettage may not be possible in extensive lesions and resection carries high...
9.
Lee L, Holman A, Li X, Vasiljevski E, ODonohue A, Cheng T, et al.
Bone
. 2022 Mar;
159:116378.
PMID: 35257929
Introduction: Osteogenesis imperfecta (OI) or brittle bone disease is a genetic disorder that results in bone fragility. Bisphosphonates such as zoledronic acid (ZA) are used clinically to increase bone mass...
10.
Vasiljevski E, Burns J, Bray P, Donlevy G, Mudge A, Jones K, et al.
Am J Med Genet A
. 2021 Jun;
185(10):2976-2985.
PMID: 34155781
Reduced muscle tone, muscle weakness, and physical fatigue can impact considerably on quality of life for children with neurofibromatosis type 1 (NF1). Human muscle biopsies and mouse models of NF1...